Gentler chemo dose offers hope for frail breast cancer patients
NCT ID NCT06105684
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a lower daily dose of the chemotherapy drug capecitabine in 40 patients aged 60 or older, or those who are frail, with advanced breast cancer. The goal is to see if this gentler dose can still shrink tumors while causing fewer side effects. Participants will take one pill daily and be monitored every 12 weeks for response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Could a personal coach at home boost energy for cancer patients?
- Can an immune booster help chemotherapy fight metastatic breast cancer?
- Can a Four-Drug cocktail tame a tough breast cancer?
- Can a new drug outsmart resistant breast cancer?